INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

FDA Approved	Therapy Name & Disease	Therapy Description	Embarc Inclusion Date*	Contractual Limitations
2025	**Waskyra™** Wiskott-Aldrich syndrome (WAS)	Administered via one-time IV infusion in patients six months and older with a confirmed mutation in the WAS gene	7/1/2026	N/A
2025	**Encelto™** Macular telangiectasia type 2 (MacTel)	Cell-based gene therapy administered via one-time surgical implantation into the eye to help slow disease progression	7/1/2026	N/A
2025	**Itvisma®** Spinal Muscular Atrophy (SMA)	Viral vector gene therapy administered via a one-time intrathecal injection for individuals two years of age and older with a confirmed mutation in the SMN1 gene	7/1/2026	N/A
2024	**Elevidys®** Duchenne muscular dystrophy (DMD)	An adeno-associated virus vector-based gerne therapy indicated for the treatment of patients four years of age or older who are ambulatory and have a confirmed mutation of the DMD gene	7/1/2026	N/A

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: April 15, 2026

INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

2024		**Kebilidi™** Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency	Aims to correct the genetic cause of AADC deficiency, a rare nervous system disorder causing problems with motor control, muscle weakness, and delayed development	7/1/2025	N/A
2024		**Lenmeldy™** Metachromatic leukodystrophy	For the treatment of a rare disease that affects the brains and nervous systems of children in their late infantile and early juvenile years	8/1/2024	N/A
2024		**Casgevy®** Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	4/1/2024	N/A
2023		**Casgevy®** Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It's lifelong but manageable with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)	4/1/2024	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution's clinical and network criteria for Casgevy (for the treatment of sickle cell disease) will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection. **No longer in effect as of 7/1/2026.**

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: April 15, 2026

INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

2023		**Lyfgenia™** Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It's lifelong but manageable with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)	4/1/2024	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution's clinical and network criteria for Lyfgenia will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection. **No longer in effect as of 7/1/2026.**
2022		**Hemgenix®** Hemophilia B	For the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes	3/1/2023	N/A
2022		**Skysona™** Adrenoleukodystrophy	To slow the progress of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)	12/1/2022	N/A
2022		**Zynteglo™** Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	8/1/2022	N/A

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: April 15, 2026

INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

2019		**Zolgensma®** Spinal Muscular Atrophy (SMA)	A gene therapy for children under two years of age with spinal muscular atrophy	7/1/2020	The financial protection against the high cost of Zolgensma applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan. **No longer in effect as of 7/1/2026.**
2017		**Luxturna®** Retinal Dystrophy	The first FDA-approved prescription gene therapy for people with inherited retinal disease	7/1/2020	

*Embarc Inclusion Date is, for each Embarc gene therapy, the date that such Embarc gene therapy is made a part of the Embarc Services. Financial protection applies when medical necessity review requests are received after the Embarc Inclusion Date for employers actively enrolled in Embarc Benefit Protection.

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: April 15, 2026